Abstract 3180
Background
Hepatic stone or lithiasis is a known risk factor for intrahepatic cholangiocarcinoma (ICC) in clinic, however the process and genomic background of the hepatobiliary lithiasis associated cholangiocarcinoma (BCAC) is completely unknown.
Methods
Here, we retrospectively collected 81 paired intrahepatic cholangiocarcinoma (ICC) frozen cancerous and adjacent tissues including those patients combining biliary calculi. Whole exome sequence (WES, average 400x) and RNA-seq were applied to characterize this cohort.
Results
Among them, prognosis of 64 patients from 2011 to 2013 revealed that BCAC had poor overall survival (18.6 months vs 28.6 months, P = 0.024, Kaplan-Meier) compared to those of non-stone ICC. WES of 81 ICC patients showed that BCAC displayed a distinct mutation pattern, with EPHA2 and SMAD4 genes significantly enriched in BCAC (P < 0.05, Fisher exact test) and epigenetic regulators IDH1, BAP1 and calcium channel RYR1 more enriched in non-calculi ICCs. Transcriptome profile showed that BCAC was different from canonical ICCs. Gene set enrichment analysis revealed that RESPONSE_TO_LIPID and CALCIUM_ION_BINDING were among the top significant changed gene sets, which might play important roles in BCACs.
Conclusions
Our results demonstrate that BCAC is a distinct CCAs subtype and biliary calculi might be an independent factor for ICC and result in a poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BGI-Shenzhen.
Funding
Shenzhen Science and Technology Innovation Committee.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract